FDA VRBPAC Hopelessly Chasing Outgoing XBB.1.5 as Fall Target
Strain is 27% and Shrinking Fast--New Vaccine will be Obsolete on Arrival
By Peter A. McCullough, MD, MPH
From Rita Rubin, Science Reporter for JAMA: “On June 15, members of the US Food and Drug Administration’s (FDA) Vaccine and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend updating the COVID-19 vaccine composition to a monovalent XBB lineage.
On June 16, the FDA announced that it had advised manufacturers planning to update their COVID-19 vaccines that they should specifically target XBB.1.5. Scientists from Moderna, Novavax, and Pfizer had told the FDA and its advisory committee that their XBB.1.5 monovalent vaccines could be ready to inject into arms by late July or early fall.
Although the FDA decides what antigens the COVID-19 vaccines should include, the US Centers for Disease Control and Prevention (CDC) is responsible for deciding who should get them and when. As soon as the FDA greenlights an XBB.1.5 vaccine, “I’m sure the ACIP will have a specially called meeting” to decide how it should be used, William Schaffner, MD, chair of the department of preventive medicine at the Vanderbilt University School of Medicine, said in an interview.
ACIP stands for the CDC’s Advisory Committee on Immunization Practices, on which Schaffner serves as the liaison representing the National Foundation for Infectious Diseases, where he is medical director. At the ACIP meeting on an XBB.1.5 vaccine, “I think there will be a rather elaborate discussion on who will receive this vaccine,” Schaffner predicted.”
Shaffner and the VRBPAC should take a look at the CDC Nowcast System which shows XBB.1.5 at 27% of strains and falling fast. That means by the the fall the new monovalent XBB.1.5 vaccine would be completely obsolete. It appears that the FDA, CDC, and vaccine developers will never be able to get ahead of the now weakened but agile Omicron strains. They have still not addressed unacceptable safety data which overshadows discussions on “who should receive the product.”
Please subscribe as a paying or founder member so we can continue to bring you the truth.
Courageous Discourse™ with Dr. Peter McCullough & John Leake is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.